US 11,891,604 B2
Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease
Jung-Joon Sung, Seoul (KR); and Ki Yoon Kim, Seoul (KR)
Assigned to CURAMYS CO., LTD., Seoul (KR)
Filed by CURAMYS CO., LTD., Seoul (KR)
Filed on Dec. 17, 2021, as Appl. No. 17/554,285.
Application 17/554,285 is a division of application No. 16/791,185, filed on Feb. 14, 2020, granted, now 11,286,484.
Application 16/791,185 is a continuation in part of application No. PCT/KR2018/009461, filed on Aug. 17, 2018.
Claims priority of application No. 10-2017-0105029 (KR), filed on Aug. 18, 2017; and application No. 10-2018-0092805 (KR), filed on Aug. 9, 2018.
Prior Publication US 2022/0186220 A1, Jun. 16, 2022
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61P 21/00 (2006.01); C12Q 1/6883 (2018.01)
CPC C12N 15/113 (2013.01) [A61P 21/00 (2018.01); C12Q 1/6883 (2013.01); C12N 2310/141 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 4 Claims
 
1. A method for treating a muscle disease
wherein the muscle disease is caused by a SOD1 or a dystrophin gene mutation, the method including: administering a composition comprising a pharmaceutically effective amount of miR-18b to a subject, wherein the muscle disease caused by a SOD1 or a dystrophin gene mutation is selected from the group consisting of Duchenne muscular dystrophy, Becker muscular dystrophy, SOD1-associated muscular atrophy, and amyotrophic lateral sclerosis.